676448-17-2

Basic information

• Product Name: 4-BROMOINDOLE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 4-BROMOINDOLE-1-CARBOXYLIC ACID TERT-BUTYL ESTER, 95+%;tert-butyl 4-bromo-1H-indole-1-carboxylate;1-Boc-4-bromoindole;N-Boc-4-bromoindole;4-Bromo-1H-indole, N-BOC protected 95%;tert-Butyl 4-bromo-1H-indole-1-carboxylate, 4-Bromo-1-(tert-butoxycarbonyl)-1H-indole;4-BROMOINDOLE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;4-BROMOINDOLE, N-BOC PROTECTED
• CAS NO: 676448-17-2
• Molecular Formula: C₁₃H₁₄BrNO₂
• Molecular Weight: 296.16
• Product Categories: Indole;API intermediates
• Mol File: 676448-17-2.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 367.9 °C at 760 mmHg
• Flash Point: 176.3 °C
• Appearance: /
• Density: 1.37g/cm³
• Refractive Index: 1.599
• Storage Temp.: Room temperature.
• Solubility: Chloroform (Slightly, Heated, Sonicated)
• CAS DataBase Reference: 4-BROMOINDOLE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMOINDOLE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(676448-17-2)
• EPA Substance Registry System: 4-BROMOINDOLE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(676448-17-2)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 676448-17-2(Hazardous Substances Data)

Usage

General Description

4-Bromoindole-1-carboxylic Acid Tert-Butyl Ester is a specialized chemical compound that combines indole and tert-butyl ester. The term "4-Bromo" suggests its bromine-substituted, specifically positioned at the fourth carbon in the indole structure. Indole is a heterocyclic aromatic compound, which is the parent structure of many natural substances. Carboxylic acid refers to the presence of a carboxyl functional group, while the Tert-butyl ester refers to an ester derivative with a tertiary butyl group. This chemical compound has specific applications in the field of biochemical research, and it is commonly used as an intermediate in organic synthesis.

InChI:InChI=1/C12H13BrN2O2/c1-12(2,3)17-11(16)15-10-6-4-5-9(13)8(10)7-14-15/h4-7H,1-3H3

Upstream product

• 52488-36-5 4-bromo-1H-indole 
• 34619-03-9 tert-butyldicarbonate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 6627-89-0 tert-butyl phenyl carbonate 
• 1195931-67-9 tert-butyl 4-(((trifluoromethyl)sulfonyl)oxy)-1H-indole-1-carboxylate 

Downstream Products

• 957034-29-6 4-bromo-1-(tert-butoxycarbonyl)-1H-indol-2-ylboronic acid 
• 893441-86-6 1,1-dimethylethyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate 
• 460096-34-8 tert-butyl 4-formyl-1H-indole-1-carboxylate 
• 252978-89-5 4-(1H-indol-4-yl)-piperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Rhodium(II)-Catalyzed [4+3] Cyclization of Triazoles with Indole Derivatives and Its Application in the Total Synthesis of (±)-Aurantioclavine

An efficient rhodium(II)-catalyzed [4+3] cyclization reaction of 1-sulfonyl-1,2-3-triazoles and indoles was developed. Azepino[5,4,3- cd]indoles, which are widely distributed in ergot alkaloids with various biological activities, could be obtained in good

Substituted olefin compound, and preparation method and application thereof

The invention provides a substituted olefin compound, and a preparation method and application thereof. Specifically, the application provides a substituted olefin compound, a stereoisomer, prodrug, solvate, and pharmaceutically acceptable salt or ester of the substituted olefin compound, a preparation method of the substituted olefin compound, and an application in preparing medicines for treating diseases relative to an excessive activity of estrogen receptors (such as ERalpha).

3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.